BACKGROUND AND OBJECTIVES. Leucovorin, or folinic acid (vitamin B9), is approved by the Food and Drug Administration (FDA) to reduce adverse effects from antifolate cancer treatments including methotr...

Expansion of the Medicare drug price negotiation rare disease drug carve-out would unnecessarily limit the number of drugs eligible for negotiation, allow for continued high drug prices for products that earn billions of dollars in Medicare, and introduce a new set of misaligned incentives.

Truth, Power, and the Drugs You Take

ALT: two men are sitting at a table with the caption what would you say you do here ?

Some see the DOJ filing as a sign the Trump administration is willing to maintain the controversial program.

What we’ve learned, and how you can help us learn more

When politicians subordinate scientific institutions to electoral interests, they undermine immediate public health efforts and inflict lasting damage on institutional credibility.

Medicare has selected 15 more drugs to negotiate directly with participating drug companies. Building on the success of the first round of negotiations, the aim is to lower prices for some more of the...

This Viewpoint focuses on the Manufacturer Discount Program, identifying 4 key themes of interest to policymakers that may be affected by its Part D redesign.

While some agree with Robert F. Kennedy Jr. that the agency needs reform, their ideas for fixing it are very different from his.

As various reform ideas are proposed, the organized medical and scientific community will need to work with the new leadership at the FDA to promote positive change–and oppose initiatives that undermi...

This study examines the characteristics of academic researchers who obtained US government–linked drug patents.

Apply by December 1, 2024 to be a PORTAL Postdoctoral or General Medicine Fellow. We are also accepting applications for a Faculty Member in Health Policy or Health Services Research.

Audio Interview from the New England Journal of Medicine — Interview with Benjamin Rome on the results of the initial round of drug-price negotiation under the Inflation Reduction Act.

Audio Interview from the New England Journal of Medicine — Interview with Benjamin Rome on the results of the initial round of drug-price negotiation under the Inflation Reduction Act.

Alt: Quote from Succession: But you are not serious people

This study examines state Medicaid coverage policies for antiobesity medications and their trends in Medicaid reimbursement from 2011 to 2022.

Some countries are moving to digital prescription drug information for patients. The U.S. shouldn’t follow suit.

This cross-sectional study compares price data for ocrelizumab and rituximab to estimate the savings to Medicare and Medicaid if rituximab were used in the trea

With more than 700 of OpenAI’s nearly 800 staff members saying they might head to Microsoft, prospects for the A.I. start-up aren’t rosy. The industry could experience second-order effects, too.